Innovating Works

PERPLASTIC II

Inactiva
GlycoTherapy: New frontiers in advanced glycotherapy for cancer PERPLASTIC II participó en un H2020: ERC-2020-COG Cancer remains a major cause of death despite phenomenal progress in current immunotherapy, that aims to boost host immune responses of anti...
2021-04-13 - 2027-11-30 | Financiado
HEALTHYFOETUS: Unravelling the effect of divergent concentrations of progesterone in early pregnancy on foetal deve... PERPLASTIC II participó en un H2020: H2020-MSCA-IF-2020 Uterine receptivity and the dialogue between the embryo and the mother in early pregnancy is mainly driven by the concentrations of the ster...
2021-03-24 - 2023-08-31 | Financiado
CareHD: Patient Centered Connected Health Model of Care for Huntingtons Disease PERPLASTIC II participó en un H2020: H2020-MSCA-RISE-2017 HD is a monogentic disease, meaning modification in a single gene occurring in all cells of the body. In Western countries it is estimated t...
2017-11-24 - 2023-10-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.